Brokerages Anticipate Esperion Therapeutics Inc (ESPR) to Post -$1.80 EPS

Wall Street analysts forecast that Esperion Therapeutics Inc (NASDAQ:ESPR) will post ($1.80) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Esperion Therapeutics’ earnings. The lowest EPS estimate is ($2.05) and the highest is ($1.47). Esperion Therapeutics reported earnings of ($1.29) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 39.5%. The business is scheduled to report its next quarterly earnings report on Wednesday, February 28th.

On average, analysts expect that Esperion Therapeutics will report full-year earnings of ($7.30) per share for the current fiscal year, with EPS estimates ranging from ($7.63) to ($6.90). For the next fiscal year, analysts anticipate that the firm will post earnings of ($6.39) per share, with EPS estimates ranging from ($8.54) to ($4.65). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Esperion Therapeutics.

A number of equities research analysts have issued reports on the company. Citigroup cut Esperion Therapeutics from a “buy” rating to a “neutral” rating and raised their target price for the company from $77.00 to $96.00 in a research note on Monday, January 22nd. Stifel Nicolaus set a $105.00 target price on Esperion Therapeutics and gave the company a “buy” rating in a research note on Monday, January 15th. BidaskClub upgraded Esperion Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 13th. Credit Suisse Group assumed coverage on Esperion Therapeutics in a research note on Wednesday, January 17th. They issued an “outperform” rating and a $103.00 target price on the stock. Finally, UBS Group set a $88.00 target price on Esperion Therapeutics and gave the company a “buy” rating in a research note on Wednesday, January 17th. Six investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. Esperion Therapeutics presently has an average rating of “Buy” and a consensus price target of $77.23.

Shares of Esperion Therapeutics (NASDAQ ESPR) opened at $65.94 on Tuesday. The stock has a market capitalization of $1,690.00, a price-to-earnings ratio of -9.61 and a beta of 2.64. Esperion Therapeutics has a one year low of $13.41 and a one year high of $82.18.

In related news, Director Nicole Vitullo sold 9,326 shares of Esperion Therapeutics stock in a transaction dated Wednesday, December 6th. The shares were sold at an average price of $53.85, for a total transaction of $502,205.10. Following the sale, the director now directly owns 2,472 shares in the company, valued at $133,117.20. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 32.50% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Voya Investment Management LLC raised its stake in shares of Esperion Therapeutics by 12.7% during the second quarter. Voya Investment Management LLC now owns 7,148 shares of the biopharmaceutical company’s stock valued at $331,000 after purchasing an additional 806 shares in the last quarter. TIAA CREF Investment Management LLC grew its holdings in Esperion Therapeutics by 3.0% during the second quarter. TIAA CREF Investment Management LLC now owns 39,074 shares of the biopharmaceutical company’s stock worth $1,808,000 after acquiring an additional 1,148 shares during the period. Alliancebernstein L.P. grew its holdings in Esperion Therapeutics by 5.3% during the second quarter. Alliancebernstein L.P. now owns 30,070 shares of the biopharmaceutical company’s stock worth $1,392,000 after acquiring an additional 1,500 shares during the period. First Mercantile Trust Co. grew its holdings in Esperion Therapeutics by 56.0% during the fourth quarter. First Mercantile Trust Co. now owns 4,233 shares of the biopharmaceutical company’s stock worth $279,000 after acquiring an additional 1,519 shares during the period. Finally, Parametric Portfolio Associates LLC grew its holdings in Esperion Therapeutics by 3.4% during the second quarter. Parametric Portfolio Associates LLC now owns 50,420 shares of the biopharmaceutical company’s stock worth $2,333,000 after acquiring an additional 1,658 shares during the period. Institutional investors and hedge funds own 92.85% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/02/06/brokerages-anticipate-esperion-therapeutics-inc-espr-to-post-1-80-eps.html.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Get a free copy of the Zacks research report on Esperion Therapeutics (ESPR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply